In a generally healthy adult with mildly to moderately elevated triglycerides who is not taking triglyceride‑lowering therapy, can citrus bergamot extract or berberine be used to lower triglyceride levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Citrus Bergamot and Berberine for Triglyceride Reduction

Neither citrus bergamot extract nor berberine should be used as primary therapy for triglyceride lowering in place of guideline-directed interventions (statins, lifestyle modification, or fibrates when indicated), as they lack robust cardiovascular outcome data and are not endorsed by major lipid management guidelines. 1

Guideline Position on Nutraceuticals for Hypertriglyceridemia

  • The American College of Cardiology (ACC) and American Heart Association (AHA) guidelines do not list citrus bergamot or berberine as therapeutic options for hypertriglyceridemia. 1 These guidelines prioritize interventions with proven mortality benefit: statins for LDL-C and cardiovascular risk reduction, fibrates for severe hypertriglyceridemia (≥500 mg/dL) to prevent pancreatitis, and icosapent ethyl (prescription EPA) for residual cardiovascular risk in high-risk patients with elevated triglycerides. 1

  • Guideline-directed care emphasizes lifestyle modification as the foundation (5–10% weight loss, added sugar restriction to <6% of calories, saturated fat <7% of calories, ≥150 min/week aerobic exercise, alcohol limitation), which can lower triglycerides by 20–70%. 1 When pharmacotherapy is needed, statins are first-line for moderate hypertriglyceridemia (200–499 mg/dL) in patients with elevated cardiovascular risk (10-year ASCVD risk ≥7.5%, diabetes age 40–75, or established ASCVD), providing 10–30% triglyceride reduction plus proven cardiovascular mortality benefit. 1, 2

Evidence for Citrus Bergamot Extract

Lipid-Lowering Effects (Research Data)

  • A 2020 systematic review of 12 studies (442 total screened) found that 75% of trials showed significant reductions in total cholesterol (12.3–31.3%), LDL-C (7.6–40.8%), and triglycerides (11.5–39.5%) with bergamot supplementation. 3 Eight trials reported HDL-C increases. The review noted a possible dose-dependent effect and potential synergy when combined with statins, particularly in statin-intolerant subjects. 3

  • A 2015 prospective study (n=80,6 months) using Bergavit® (150 mg flavonoids daily: 16% neoeriocitrin, 47% neohesperidin, 37% naringin) in subjects with moderate hypercholesterolemia (LDL-C 160–190 mg/dL) showed: 4

    • Total cholesterol decreased from 6.6±0.4 to 5.8±1.1 mmol/L (p<0.0001)
    • Triglycerides decreased from 1.8±0.6 to 1.5±0.9 mmol/L (p=0.0020)
    • LDL-C decreased from 4.6±0.2 to 3.7±1.0 mmol/L (p<0.0001)
    • HDL-C increased from 1.3±0.2 to 1.4±0.4 mmol/L (p<0.0007)
    • Small dense LDL particles (LDL-3, -4, -5) decreased significantly
    • Carotid intima-media thickness decreased from 1.2±0.4 to 0.9±0.1 mm (p<0.0001) 4

  • A 2024 randomized controlled trial (n=64,4 months) using standardized bergamot extract (150 mg flavonoids/day) in subjects with high cholesterol demonstrated: 5

    • Total cholesterol decreased by 8.8%
    • LDL-C decreased by 11.5%
    • HDL-C increased by 5.5% (trending toward significance)
    • Oxidized LDL decreased by 2.0%
    • Paraoxonase activity (PON1) increased by 6.5%
    • No changes in weight, blood pressure, hepatic or renal function markers (good tolerability) 5

Limitations and Contradictory Evidence

  • A 2024 randomized controlled trial (n=45,12 weeks) of a bergamot-based beverage (400 mL/day, bergamot juice ≤25%) in healthy subjects found no significant between-group differences in lipid parameters, glucose, insulin, or inflammatory markers. 6 Both intervention and control groups showed time-related decreases in total cholesterol, fasting glucose, insulin, BMI, and waist circumference, but these were attributed to dietary counseling provided to both groups. 6 Notably, urinary bergamot-derived HMG-containing flavanones or metabolites were not detectable, raising questions about bioavailability at this concentration. 6

  • The 2020 systematic review noted that studies had heterogeneous designs and limited scientific quality, with small sample sizes, variable bergamot preparations, and lack of standardization. 3 Most studies were conducted in subjects with dyslipidemia rather than isolated hypertriglyceridemia, and none assessed cardiovascular outcomes (myocardial infarction, stroke, cardiovascular death). 3

Evidence for Berberine

Lipid-Lowering Effects (Research Data)

  • A 2018 systematic review and meta-analysis of 16 RCTs (n=2,147) found that berberine significantly reduced: 7

    • Total cholesterol: MD -0.47 mmol/L (95% CI -0.64 to -0.31, p<0.00001)
    • LDL-C: MD -0.38 mmol/L (95% CI -0.53 to -0.22, p<0.00001)
    • Triglycerides: MD -0.28 mmol/L (95% CI -0.46 to -0.10, p=0.002)
    • HDL-C increased when berberine was used alone: MD 0.08 mmol/L (95% CI 0.03 to 0.12, p=0.001) 7

  • A 2024 meta-analysis of 41 RCTs (n=4,838,8–18 weeks) assessing berberine alone or combined with other nutraceuticals showed: 8

    • Total cholesterol: MD -17.42 mg/dL (95% CI -22.91 to -11.93)
    • LDL-C: MD -14.98 mg/dL (95% CI -20.67 to -9.28)
    • Triglycerides: MD -18.67 mg/dL (95% CI -25.82 to -11.51)
    • HDL-C: MD 1.97 mg/dL (95% CI 1.16 to 2.78)
    • Products with berberine alone had less robust effects on total cholesterol (MD -12.08 mg/dL) and LDL-C (MD -9.26 mg/dL), but similar triglyceride effects (MD -17.40 mg/dL). 8
    • Berberine combined with red yeast rice or Silybum marianum showed greater reductions in total cholesterol and LDL-C. 8

  • A 2023 systematic review and meta-analysis of 18 RCTs (n=1,788,4–24 weeks, mainly conducted in mainland China and Hong Kong) found: 9

    • LDL-C: -0.46 mmol/L (95% CI -0.62 to -0.30,14 studies, n=1,447)
    • Total cholesterol: -0.48 mmol/L (95% CI -0.63 to -0.33,17 studies, n=1,637)
    • Triglycerides: -0.34 mmol/L (95% CI -0.46 to -0.23,18 studies, n=1,661)
    • Apolipoprotein B: -0.25 g/L (95% CI -0.40 to -0.11,2 studies, n=127)
    • HDL-C: 0.06 mmol/L (95% CI 0.00 to 0.11,15 studies, n=1,471), with a notable sex-specific effect: women showed an increase of 0.11 mmol/L (95% CI 0.09 to 0.13), while men showed a decrease of -0.07 mmol/L (95% CI -0.16 to 0.02). 9

  • A 2007 single-blind clinical trial (n=40,4 weeks) comparing berberine alone versus a combination product (berberine + policosanol + red yeast extract + folic acid + astaxanthin) in subjects with moderate dyslipidemia showed: 10

    • Berberine alone reduced total cholesterol by 16%, LDL-C by 20%, apoB by 15%, triglycerides by 22%, and increased HDL-C by 6.6%.
    • The combination product reduced total cholesterol by 20%, LDL-C by 25%, apoB by 29%, triglycerides by 26%, and increased HDL-C by 5.1%.
    • No adverse events or impairments of liver transaminases or CPK were observed. 10

Limitations and Safety Concerns

  • The 2018 meta-analysis noted high clinical heterogeneity and generally low methodological quality (risk of selection bias, performance bias, detection bias, attrition bias, and confounding bias). 7 The authors concluded that findings should be interpreted with caution and that rigorous clinical trials are needed. 7

  • The 2023 meta-analysis found no serious adverse events reported for berberine. 9 Gastrointestinal adverse events (reported in 12 of 16 studies) tended to be more frequent in berberine groups versus placebo (2–23% vs 2–15%). 9 No muscle-related adverse events were reported. 9

  • The 2024 meta-analysis (n=4,838) reported no significant differences in adverse event incidence between berberine and control groups (RR=0.64,95% CI 0.31 to 1.30, p=0.22), with no severe adverse effects in either group. 8

  • FDA labeling for berberine products advises: "If pregnant or breast-feeding ask a health professional before use." 11 Berberine content in homeopathic preparations is extremely low (e.g., <10^-12 mg hydrastine/berberine alkaloids per pellet, containing 0.443 mg active ingredient per pellet). 11

Comparative Efficacy: Nutraceuticals vs. Guideline-Directed Therapy

Proven Therapies with Cardiovascular Outcome Data

  • Statins reduce major adverse cardiovascular events by 20–25% per 1.0 mmol/L LDL-C reduction (robust RCT data). 1 For moderate hypertriglyceridemia (200–499 mg/dL) with elevated cardiovascular risk, statins are first-line, providing 10–30% triglyceride reduction plus proven mortality benefit. 1, 2

  • Icosapent ethyl (prescription EPA, 4 g/day) reduces cardiovascular events by ≈25% in high-risk patients with elevated triglycerides (≥150 mg/dL) on statin therapy (REDUCE-IT trial, NNT=21 over 4.9 years). [1, @{"type":"guideline","title":"Prescription Omega‑3 Fatty Acids (Icosapent Ethyl) for Hypertriglyceridemia on Background Statin Therapy – ACC Guidance [@{"id":"1","title":"2021 acc expert consensus decision pathway on the management of ascvd risk reduction in patients with persistent hypertriglyceridemia: a report of the american college of cardiology solution set oversight committee.","url":"https://pubmed.ncbi.nlm.nih.gov/34332805/\",\"type\":\"guideline\",\"year\":2021,\"source\":\"Journal of the American College of Cardiology","source_id":"6dd24c7163f1a016b8ecbcaa58ee3fad"}@]","source_id":"chapter_390c5a88-9409-45f0-8a6c-65c4275a91df","url":"https://droracle.ai/guidelines/390c5a88-9409-45f0-8a6c-65c4275a91df","year":2026,"source":"Praxis Medical Insights: Practical Summaries of Clinical Guidelines","id":13}@] This is the only triglyceride-lowering agent FDA-approved for cardiovascular risk reduction. [1, @{"type":"guideline","title":"Prescription Omega‑3 Fatty Acids (Icosapent Ethyl) for Hypertriglyceridemia on Background Statin Therapy – ACC Guidance [@{"id":"1","title":"2021 acc expert consensus decision pathway on the management of ascvd risk reduction in patients with persistent hypertriglyceridemia: a report of the american college of cardiology solution set oversight committee.","url":"https://pubmed.ncbi.nlm.nih.gov/34332805/\",\"type\":\"guideline\",\"year\":2021,\"source\":\"Journal of the American College of Cardiology","source_id":"6dd24c7163f1a016b8ecbcaa58ee3fad"}@]","source_id":"chapter_390c5a88-9409-45f0-8a6c-65c4275a91df","url":"https://droracle.ai/guidelines/390c5a88-9409-45f0-8a6c-65c4275a91df","year":2026,"source":"Praxis Medical Insights: Practical Summaries of Clinical Guidelines","id":13}@]

  • Fenofibrate (54–160 mg daily) reduces triglycerides by 30–50% and is indicated for severe hypertriglyceridemia (≥500 mg/dL) to prevent acute pancreatitis. 1 However, the ACCORD trial showed no cardiovascular event reduction when fenofibrate was added to simvastatin in diabetics. 1

Nutraceutical Effects in Context

  • Citrus bergamot extract (150 mg flavonoids/day) reduced triglycerides by 11.5–39.5% in dyslipidemic subjects 3, with one study showing a 2.0% reduction (from 1.8±0.6 to 1.5±0.9 mmol/L, p=0.0020). 4 However, a trial in healthy subjects found no effect. 6

  • Berberine reduced triglycerides by 0.28–0.34 mmol/L (≈7–30 mg/dL) in meta-analyses of dyslipidemic cohorts. 7, 9 This is modest compared to statins (10–30% reduction), fibrates (30–50% reduction), or icosapent ethyl (20–30% reduction with proven cardiovascular benefit). [1, @{"type":"guideline","title":"Prescription Omega‑3 Fatty Acids (Icosapent Ethyl) for Hypertriglyceridemia on Background Statin Therapy – ACC Guidance [@{"id":"1","title":"2021 acc expert consensus decision pathway on the management of ascvd risk reduction in patients with persistent hypertriglyceridemia: a report of the american college of cardiology solution set oversight committee.","url":"https://pubmed.ncbi.nlm.nih.gov/34332805/\",\"type\":\"guideline\",\"year\":2021,\"source\":\"Journal of the American College of Cardiology","source_id":"6dd24c7163f1a016b8ecbcaa58ee3fad"}@]","source_id":"chapter_390c5a88-9409-45f0-8a6c-65c4275a91df","url":"https://droracle.ai/guidelines/390c5a88-9409-45f0-8a6c-65c4275a91df","year":2026,"source":"Praxis Medical Insights: Practical Summaries of Clinical Guidelines","id":13}@]

  • Neither citrus bergamot nor berberine has cardiovascular outcome data (myocardial infarction, stroke, cardiovascular death). 3, 7, 9 In contrast, statins and icosapent ethyl have Level A evidence from large RCTs demonstrating mortality benefit. [1, @{"type":"guideline","title":"Prescription Omega‑3 Fatty Acids (Icosapent Ethyl) for Hypertriglyceridemia on Background Statin Therapy – ACC Guidance [@{"id":"1","title":"2021 acc expert consensus decision pathway on the management of ascvd risk reduction in patients with persistent hypertriglyceridemia: a report of the american college of cardiology solution set oversight committee.","url":"https://pubmed.ncbi.nlm.nih.gov/34332805/\",\"type\":\"guideline\",\"year\":2021,\"source\":\"Journal of the American College of Cardiology","source_id":"6dd24c7163f1a016b8ecbcaa58ee3fad"}@]","source_id":"chapter_390c5a88-9409-45f0-8a6c-65c4275a91df","url":"https://droracle.ai/guidelines/390c5a88-9409-45f0-8a6c-65c4275a91df","year":2026,"source":"Praxis Medical Insights: Practical Summaries of Clinical Guidelines","id":13}@]

Clinical Practice Recommendations

When Nutraceuticals Should NOT Be Used

  • Do not postpone evidence-based pharmacotherapy (statins, fibrates, icosapent ethyl) while trialing citrus bergamot or berberine in patients at elevated cardiovascular risk or with severe hypertriglyceridemia. 1 For example, a patient with triglycerides ≥500 mg/dL requires immediate fenofibrate to prevent pancreatitis; delaying this for a nutraceutical trial is inappropriate. 1

  • Do not substitute citrus bergamot or berberine for proven lifestyle interventions (5–10% weight loss, added sugar restriction to <6% of calories, saturated fat <7% of calories, ≥150 min/week aerobic exercise, alcohol limitation), which can lower triglycerides by 20–50% and confer cardiovascular benefit. 1

  • Do not use citrus bergamot or berberine as monotherapy in patients with moderate hypertriglyceridemia (200–499 mg/dL) and elevated cardiovascular risk (10-year ASCVD risk ≥7.5%, diabetes age 40–75, or established ASCVD). 1, 2 These patients require statin therapy for proven mortality benefit. 1, 2

Potential Role as Adjunctive Therapy (Off-Guideline)

  • If a patient refuses statins or is statin-intolerant, citrus bergamot (150 mg flavonoids/day) or berberine (500–1500 mg/day) may be considered as adjunctive therapy to intensive lifestyle modification for mild-to-moderate hypertriglyceridemia (150–499 mg/dL) in low-risk individuals (10-year ASCVD risk <7.5%, no diabetes, no established ASCVD). 3, 7, 9 However, this is not guideline-endorsed and should be accompanied by close lipid monitoring (fasting lipid panel every 6–12 weeks). 1

  • Citrus bergamot or berberine should not replace prescription omega-3 therapy (icosapent ethyl) in patients who meet criteria for cardiovascular risk reduction (triglycerides ≥150 mg/dL on maximally tolerated statin, LDL-C <100 mg/dL, and established ASCVD or diabetes + ≥2 risk factors). [1, @{"type":"guideline","title":"Prescription Omega‑3 Fatty Acids (Icosapent Ethyl) for Hypertriglyceridemia on Background Statin Therapy – ACC Guidance [@{"id":"1","title":"2021 acc expert consensus decision pathway on the management of ascvd risk reduction in patients with persistent hypertriglyceridemia: a report of the american college of cardiology solution set oversight committee.","url":"https://pubmed.ncbi.nlm.nih.gov/34332805/\",\"type\":\"guideline\",\"year\":2021,\"source\":\"Journal of the American College of Cardiology","source_id":"6dd24c7163f1a016b8ecbcaa58ee3fad"}@]","source_id":"chapter_390c5a88-9409-45f0-8a6c-65c4275a91df","url":"https://droracle.ai/guidelines/390c5a88-9409-45f0-8a6c-65c4275a91df","year":2026,"source":"Praxis Medical Insights: Practical Summaries of Clinical Guidelines","id":13}@] Icosapent ethyl has proven cardiovascular outcome benefit (25% relative risk reduction in MACE), which nutraceuticals lack. [1, @{"type":"guideline","title":"Prescription Omega‑3 Fatty Acids (Icosapent Ethyl) for Hypertriglyceridemia on Background Statin Therapy – ACC Guidance [@{"id":"1","title":"2021 acc expert consensus decision pathway on the management of ascvd risk reduction in patients with persistent hypertriglyceridemia: a report of the american college of cardiology solution set oversight committee.","url":"https://pubmed.ncbi.nlm.nih.gov/34332805/\",\"type\":\"guideline\",\"year\":2021,\"source\":\"Journal of the American College of Cardiology","source_id":"6dd24c7163f1a016b8ecbcaa58ee3fad"}@]","source_id":"chapter_390c5a88-9409-45f0-8a6c-65c4275a91df","url":"https://droracle.ai/guidelines/390c5a88-9409-45f0-8a6c-65c4275a91df","year":2026,"source":"Praxis Medical Insights: Practical Summaries of Clinical Guidelines","id":13}@]

Safety and Monitoring

  • Citrus bergamot extract (150 mg flavonoids/day) appears well-tolerated with no reported adverse effects on liver or renal function in trials up to 6 months. 4, 5 However, long-term safety data are lacking. 3

  • Berberine is generally well-tolerated, with gastrointestinal adverse events (2–23%) being the most common. 7, 9 No serious adverse events or muscle-related toxicity have been reported in meta-analyses. 7, 9 However, berberine should be avoided in pregnancy and breastfeeding unless advised by a healthcare professional. 11

  • If citrus bergamot or berberine is used, monitor fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C) at 6–12 weeks and every 3–6 months thereafter. 1 Discontinue if no lipid improvement is seen after 3 months or if adverse effects occur. 7, 9

Summary Algorithm for Triglyceride Management

  1. Assess triglyceride level and cardiovascular risk:

    • Triglycerides ≥500 mg/dL → Immediate fenofibrate (54–160 mg daily) to prevent pancreatitis. 1
    • Triglycerides 200–499 mg/dL + elevated cardiovascular risk (10-year ASCVD risk ≥7.5%, diabetes age 40–75, or established ASCVD) → Moderate-to-high intensity statin (atorvastatin 10–20 mg or rosuvastatin 5–10 mg daily) immediately alongside lifestyle changes. 1, 2
    • Triglycerides 150–199 mg/dL + elevated cardiovascular risk → Consider moderate-intensity statin after shared decision-making. 1
    • Triglycerides <150 mg/dL → Lifestyle modification only (unless other indications for statin). 1

  2. Implement intensive lifestyle modification for all patients:

    • 5–10% weight loss (yields ≈20% triglyceride reduction). 1
    • Added sugars <6% of total calories (≈30 g on 2,000-kcal diet). 1
    • Total fat 30–35% of calories (or 20–25% if triglycerides 500–999 mg/dL). 1
    • Saturated fat <7% of calories; replace with monounsaturated/polyunsaturated fats. 1
    • Eliminate trans fats. 1
    • Soluble fiber >10 g/day. 1
    • ≥2 servings/week fatty fish. 1
    • ≥150 min/week moderate-intensity aerobic exercise. 1
    • Limit or avoid alcohol (complete abstinence if triglycerides ≥500 mg/dL). 1

  3. Reassess fasting lipid panel at 6–12 weeks after lifestyle changes and 4–8 weeks after statin initiation.

    • If triglycerides remain >200 mg/dL after 3 months of optimized lifestyle + statin, consider adding icosapent ethyl 2 g twice daily (if established ASCVD or diabetes + ≥2 risk factors). [1, @{"type":"guideline","title":"Prescription Omega‑3 Fatty Acids (Icosapent Ethyl) for Hypertriglyceridemia on Background Statin Therapy – ACC Guidance [@{"id":"1","title":"2021 acc expert consensus decision pathway on the management of ascvd risk reduction in patients with persistent hypertriglyceridemia: a report of the american college of cardiology solution set oversight committee.","url":"https://pubmed.ncbi.nlm.nih.gov/34332805/\",\"type\":\"guideline\",\"year\":2021,\"source\":\"Journal of the American College of Cardiology","source_id":"6dd24c7163f1a016b8ecbcaa58ee3fad"}@]","source_id":"chapter_390c5a88-9409-45f0-8a6c-65c4275a91df","url":"https://droracle.ai/guidelines/390c5a88-9409-45f0-8a6c-65c4275a91df","year":2026,"source":"Praxis Medical Insights: Practical Summaries of Clinical Guidelines","id":13}@]
    • If icosapent ethyl criteria not met but triglycerides remain >200 mg/dL, consider adding fenofibrate 54–160 mg daily. 1

  4. Citrus bergamot or berberine may be considered as adjunctive therapy (off-guideline) only in:

    • Low-risk individuals (10-year ASCVD risk <7.5%, no diabetes, no established ASCVD) with mild-to-moderate hypertriglyceridemia (150–499 mg/dL) who refuse statins or are statin-intolerant. 3, 7, 9
    • Do not use in place of guideline-directed therapy (statins, fibrates, icosapent ethyl) in patients with elevated cardiovascular risk or severe hypertriglyceridemia. 1

Key Takeaways

  • Citrus bergamot and berberine are not endorsed by ACC/AHA guidelines for triglyceride management and lack cardiovascular outcome data. 1
  • Research suggests modest lipid-lowering effects (triglycerides reduced by 11.5–39.5% with bergamot 3, 4 and 0.28–0.34 mmol/L with berberine 7, 9), but studies have heterogeneous designs, limited quality, and no mortality benefit. 3, 7, 9
  • Guideline-directed therapy (statins, lifestyle modification, fibrates for severe hypertriglyceridemia, icosapent ethyl for high-risk patients) should always take precedence due to proven cardiovascular benefit. [1, @{"type":"guideline","title":"Prescription Omega‑3 Fatty Acids (Icosapent Ethyl) for Hypertriglyceridemia on Background Statin Therapy – ACC Guidance [@{"id":"1","title":"2021 acc expert consensus decision pathway on the management of ascvd risk reduction in patients with persistent hypertriglyceridemia: a report of the american college of cardiology solution set oversight committee.","url":"https://pubmed.ncbi.nlm.nih.gov/34332805/\",\"type\":\"guideline\",\"year\":2021,\"source\":\"Journal of the American College of Cardiology","source_id":"6dd24c7163f1a016b8ecbcaa58ee3fad"}@]","source_id":"chapter_390c5a88-9409-45f0-8a6c-65c4275a91df","url":"https://droracle.ai/guidelines/390c5a88-9409-45f0-8a6c-65c4275a91df","year":2026,"source":"Praxis Medical Insights: Practical Summaries of Clinical Guidelines","id":13}@, 2]
  • If nutraceuticals are used, they should be adjunctive to intensive lifestyle modification in low-risk individuals, with close lipid monitoring and discontinuation if no benefit is seen after 3 months. 1, 3, 7, 9

References

1
Guideline

Hypertriglyceridemia Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

2
Guideline

Management of Mixed Dyslipidemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3
Research

Effect of bergamot on lipid profile in humans: A systematic review.

Critical reviews in food science and nutrition, 2020

7
Research

Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials.

Phytomedicine : international journal of phytotherapy and phytopharmacology, 2018

Related Questions

What is the recommended daily dose of berberine for lowering cholesterol?
What are the recommendations and precautions for using berberine supplements?
What is the effect of bergamot supplement on cholesterol (chol) levels?
Is it safe to take berberine with Eliquis (apixaban)?
Is it safe to take berberine and propranolol (beta blocker) together?
Is bronchial asthma possible in a patient with normal serum IgE levels?
What are the possible causes of bilateral erythema and pruritus with 0.2 cm papular lesions on the palms, soles, and axillae?
What are the differential diagnoses for oropharyngeal dysphagia?
How do I determine the appropriate intravenous iron dose based on patient weight and iron studies (transferrin saturation and ferritin) for a dialysis patient?
Should tadalafil be continued in a patient with pelvic‑floor hypertonicity causing pain and insomnia, or should it be discontinued in favor of pelvic‑floor physiotherapy and cognitive‑behavioural therapy for insomnia?
Which ultrasound modality is recommended to evaluate the ovaries?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question